| 27.98 0.29 (1.05%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 37.66  |
1-year : | 41.9 |
| Resists | First : | 32.24 |
Second : | 35.88 |
| Pivot price | 28.9 |
|||
| Supports | First : | 26.36 |
Second : | 21.93 |
| MAs | MA(5) : | 28.18  |
MA(20) : | 29.77 |
| MA(100) : | 31.65 |
MA(250) : | 39.7 |
|
| MACD | MACD : | -1.6 |
Signal : | -1.6 |
| %K %D | K(14,3) : | 26.4 |
D(3) : | 23.7 |
| RSI | RSI(14): 37.3 |
|||
| 52-week | High : | 63.08 | Low : | 19.34 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MORF ] has closed above bottom band by 28.5%. Bollinger Bands are 33.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.14 - 28.25 | 28.25 - 28.35 |
| Low: | 26.06 - 26.2 | 26.2 - 26.31 |
| Close: | 27.74 - 27.97 | 27.97 - 28.16 |
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Wed, 24 Apr 2024
What Makes Morphic (MORF) a New Buy Stock - Yahoo Finance
Tue, 23 Apr 2024
MORF NEWS: Johnson Fistel has Commenced an Investigation on Behalf of Morphic Holding Company Shareholders - GlobeNewswire
Tue, 23 Apr 2024
New Strong Sell Stocks for September 16th - Yahoo Movies Canada
Sun, 21 Apr 2024
Federated Hermes Inc. Increases Holdings in Morphic Holding, Inc. (NASDAQ:MORF) - MarketBeat
Tue, 16 Apr 2024
Morphic (NASDAQ:MORF) Stock Price Down 4.4% - MarketBeat
Mon, 15 Apr 2024
Morphic Holding, Inc. (MORF) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Movies Canada
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 3.679e+007 (%) |
| Held by Institutions | 16.7 (%) |
| Shares Short | 6,030 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.776e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -34 % |
| Return on Assets (ttm) | 296.7 % |
| Return on Equity (ttm) | -20.5 % |
| Qtrly Rev. Growth | 521000 % |
| Gross Profit (p.s.) | -70.43 |
| Sales Per Share | -20.48 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -112 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.37 |
| Price to Cash Flow | 2.83 |
| Dividend | 0 |
| Forward Dividend | 5.9e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|